Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Baxter
Harvard Business School
Moodys
AstraZeneca
McKinsey

Last Updated: September 26, 2022

Details for New Drug Application (NDA): 022051


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


NDA 022051 describes FLONASE SENSIMIST ALLERGY RELIEF, which is a drug marketed by Glaxosmithkline Cons and is included in one NDA. It is available from two suppliers. There are five patents protecting this drug. Additional details are available on the FLONASE SENSIMIST ALLERGY RELIEF profile page.

The generic ingredient in FLONASE SENSIMIST ALLERGY RELIEF is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.
Summary for 022051
Tradename:FLONASE SENSIMIST ALLERGY RELIEF
Applicant:Glaxosmithkline Cons
Ingredient:fluticasone furoate
Patents:5
Formulation / Manufacturing:see details
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 022051
Generic Entry Date for 022051*:
Constraining patent/regulatory exclusivity:
Dosage:
SPRAY, METERED;NASAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 022051
Suppliers and Packaging for NDA: 022051
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051 NDA GlaxoSmithKline Consumer Healthcare Holdings (US) LLC 0135-0615 0135-0615-01 1 BOTTLE in 1 CARTON (0135-0615-01) > 30 SPRAY, METERED in 1 BOTTLE
FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051 NDA GlaxoSmithKline Consumer Healthcare Holdings (US) LLC 0135-0615 0135-0615-02 1 BOTTLE in 1 PACKAGE (0135-0615-02) > 60 SPRAY, METERED in 1 BOTTLE

Profile for product number 002

Active Rx/OTC/Discontinued:OTCDosage:SPRAY, METERED;NASALStrength0.0275MG/SPRAY
Approval Date:Aug 2, 2016TE:RLD:Yes
Patent:See Plans and PricingPatent Expiration:Apr 5, 2026Product Flag?YSubstance Flag?Delist Request?
Patent:See Plans and PricingPatent Expiration:Oct 15, 2028Product Flag?YSubstance Flag?Delist Request?
Patent:See Plans and PricingPatent Expiration:Jul 15, 2028Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022051

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 See Plans and Pricing See Plans and Pricing
Glaxosmithkline Cons FLONASE SENSIMIST ALLERGY RELIEF fluticasone furoate SPRAY, METERED;NASAL 022051-002 Aug 2, 2016 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Merck
Mallinckrodt
Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.